1. Introduction {#sec1-ijerph-16-01772}
===============

HIV/AIDS has become one of the major global health burdens. By the end of 2017, there were 36.9 million people living with HIV (PLWH) worldwide with 1.8 million new infection cases and 940,000 deaths \[[@B1-ijerph-16-01772]\]. Among them, 39% were reported to have suffered from depression \[[@B2-ijerph-16-01772]\]. Depression is a mental health disorder that is highly prevalent, and characterized by low mood, diminished self-worth, pessimistic thoughts, poor concentration, and biological symptoms (that of poor appetite and sleep difficulties) and increased withdrawal from social activities. Along with anxiety disorder, these psychiatric problems may result in chronic detrimental impairments and could even lead to suicidal ideation \[[@B3-ijerph-16-01772]\]. According to the recent World Health Organization (WHO) report, there have been over 300 million people living with depression and nearly 800,000 patients died due to suicide each year \[[@B4-ijerph-16-01772]\]. Depressive disorders have caused over 50 million years lived with disability (YLD) worldwide, accounting for 7.5% of global total YLD and, thus, are regarded as the single largest contributor to non-fatal health loss \[[@B5-ijerph-16-01772]\].

In individuals living with HIV, depression may worsen existing disease states and lead to poorer health outcomes. Prior research has revealed that depression is not only associated with higher HIV viral loads and lower CD4 cells count but also hastens the progression to AIDS and elevates the risk of mortality \[[@B6-ijerph-16-01772],[@B7-ijerph-16-01772]\]. Furthermore, depression has been reported to reduce adherence to antiretroviral therapy (ART), weaken its therapeutic effects, and compromises the medication outcomes at both individual and population scale \[[@B8-ijerph-16-01772],[@B9-ijerph-16-01772]\]. Adherence has been universally defined as "the extent to which a person's behavior---taking medication, following a diet, and or executing lifestyle changes---corresponds with the agreed recommendations from a provider" \[[@B10-ijerph-16-01772]\]. As adherence to ART medications is instrumental in treatment effectiveness and clinical outcomes, ART interruption and discontinuation would worsen physical functioning, and along with depressive behaviors, this could result in further impairments in social relationships and a consequential reduced overall quality of life \[[@B11-ijerph-16-01772]\]. The comorbidity of HIV and depression typically results in longer onset depressive illnesses and more severe symptoms, such as higher distress and self-stigma, loss of appetite, and poorer sleep quality \[[@B12-ijerph-16-01772]\]. Additionally, the risk of experiencing moderate to severe depressive symptoms in patients that are non-adherent to ART was reported to be three-fold higher compared to adherent ones \[[@B13-ijerph-16-01772]\].

In recent years, there has been more research examining the effects of depression amongst individuals living with HIV. In 2014, a study by Arseniou et al. discussed methodology limitations and suggested further directions for diagnosis and management for depression in HIV-infected patients \[[@B14-ijerph-16-01772]\]. Maria G. Nani and colleagues reviewed the epidemiological characteristics and achievements on diagnoses and treatments for people suffering from both HIV and depression \[[@B15-ijerph-16-01772]\]. Meanwhile, depression among HIV and HCV co-infected patients was highlighted in a systematic review and meta-analysis by Renata Fialho et al. \[[@B16-ijerph-16-01772]\]. Nonetheless, to the best of our knowledge, there is currently no study performed a thorough bibliometric analysis that quantitatively and qualitatively examines the extant literature of depression in HIV population.

In order to demonstrate the global research trends as well as identify the research gaps of depression among HIV-positive people, we applied bibliometric analysis, which objectively evaluates the productivity of global researchers or institutions in this field \[[@B17-ijerph-16-01772]\]. Additionally, this study also aimed at reporting the trend of published articles over time and measured international growth based on databases of published literature. By pointing out the current trends. as well as presenting visual collaborating network of the studies on this research topic, we can effectively examine the development, productivity, and effective interventions of depression for HIV population and, thus, better inform researchers and physicians worldwide.

2. Materials and Methods {#sec2-ijerph-16-01772}
========================

2.1. Search Strategy {#sec2dot1-ijerph-16-01772}
--------------------

We chose the Web of Science as the online database to design a cross-sectional study for HIV/AIDS bibliography analyzing. The search query consisted of: HIV; human-immunodeficiency-virus, AIDS, and Acquired Immune Deficiency Syndrome (full strategy in [Table S1](#app1-ijerph-16-01772){ref-type="app"}). Document types rather than research articles and research reviews were excluded from the analysis. The language of the publications was restricted to English and only papers published before and in 2017 were chosen.

2.2. Data Extraction {#sec2dot2-ijerph-16-01772}
--------------------

Data, including authors information (name and affiliation), the title of papers, the name of journal, keywords, and abstracts, were sorted by total citations and downloaded from the Web of Science. Citation reports automatically created by the Web of Science were also downloaded. All of the downloaded data were converted to xlsm form (Microsoft Excel, version 16, Microsoft, Washington, WA, USA) for data checking error. Standardization was performed by two analysts to merge the different name abbreviations of an author. In particular, one researcher checked if the name of an author appeared in more than one form, in detail "De Clercq E" or "Declercq E", by coincidence of the authors' workplace and email as the basic normalized criteria (for instance, Katholieke Universiteit Leuven and Catholic University of Leuven are one university in Belgium), and a second researcher verified the data. The procedure was followed by the filter of all the downloaded data by eliminating articles that were: (1) unoriginal reviews and papers, (2) unrelated to HIV/AIDS, and (3) not in English. Due to the vast records related to this topic, four researchers were involved and worked dependently in data filtering. Two research teams worked independently to make sure that the results matched. One research team, based on the document types that had been shown by the Web of Science, the title, and keywords of the papers, excluded 120,187 papers. The other team applied the same process to verify the results. Any conflict was solved by discussion.

2.3. Data Analysis {#sec2dot3-ijerph-16-01772}
------------------

We analyzed data based on the total number of authors, year of publication, category, most popular keywords and their co-occurrence, citations, usages, and abstracts. After downloading and extracting data, we applied Macro, a programming code run in the Excel environment to calculate a country citation, and intra- and inter-country collaboration. A network of countries sharing co-authorships, the author keyword co-occurrence network and countries network were created by VOSviewer (version 1.6.8, Leiden University, Leiden, Netherlands). As for content analysis of the abstracts, we applied exploratory factor analysis to identify research domains emerging from all content of the abstract; loadings of 0.4 \[[@B18-ijerph-16-01772]\]. Jaccard's similarity index was utilized to identify research topics or terms most frequently co-occurring with each other \[[@B19-ijerph-16-01772]\].

3. Results {#sec3-ijerph-16-01772}
==========

3.1. Number of Published Items and Publication Trend {#sec3dot1-ijerph-16-01772}
----------------------------------------------------

[Figure 1](#ijerph-16-01772-f001){ref-type="fig"} presents the paper selecting process, in which 250,270 papers relating to HIV/AIDS were identified. Among them, 4872 publications containing the terms "depression", "depressed", "anxiety", and "mood" in either title or abstract were selected.

Not until the very first publication in 1990 did physicians start to pay more attention to depressive disorders in PLWH and significantly more papers were published, as illustrated by the considerable growth in the total number of papers over the research period. Especially in the last five years, total usage (the number of times being downloaded) and usage rates have increased highly. The papers published in 2006 have been particularly sought after, evidently by the substantial total citations ([Table 1](#ijerph-16-01772-t001){ref-type="table"}).

The number of articles counted by study settings is presented in [Table 2](#ijerph-16-01772-t002){ref-type="table"}. In total, there were 1791 cases in 60 countries. Being the epicenters of the world's largest epidemic, it was not a surprise that the United States, South Africa, and Uganda were the most well-studied populations \[[@B20-ijerph-16-01772],[@B21-ijerph-16-01772]\]. Many studies were also set up in such populous nations as China and India. Only a few study settings were located in such Asian developing countries as Vietnam, Taiwan, Thailand, etc.

3.2. Co-Authorship Network {#sec3dot2-ijerph-16-01772}
--------------------------

[Figure 2](#ijerph-16-01772-f002){ref-type="fig"} illustrates the international collaboration network of 68 countries in depression research in HIV/AIDS. The United States of America appeared to be the knowledge hub of the world in this research topic, with the largest number of publications as well as densest co-authorships network, especially with its neighbor Canada and other large HIV populations, from South Africa, Uganda, to China, Thailand, and Cambodia. The collaborating networks were also based on geographical locations. The green cluster, for instance, indicates collaboration of Western European countries, including France, Germany, Switzerland, Netherlands, and Belgium. Meanwhile, the cluster in red revealed the cooperation of Asian nations (Singapore, Taiwan, Japan, South Korea, Vietnam, and Indonesia), the Middle East (Saudi Arabia, Israel, Iran), and Africa (Nigeria, Malawi, Ethiopia, Zambia, Tanzania, and Rwanda).

3.3. Keyword Co-Occurrence and Research Domains {#sec3dot3-ijerph-16-01772}
-----------------------------------------------

Analyses of keywords and abstract's contents provided us with a better understanding of depressive disorders and related factors in PLWH. The principle components of keywords structure with the most frequent groups of terms are displayed in [Figure 3](#ijerph-16-01772-f003){ref-type="fig"}. The clusters were emerged from 373 most frequent key words co-occurrence of at least 20 times. Nodes in red point out a number of HIV risk factors and behaviors (violence, sexual abuse, substance use) affecting vulnerable subjects, including women, adolescents, gay or bisexual men, transgender, and injection drug users, in highly infected populations, such as the United States and India. Green nodes focus on symptoms of HIV infection and associated mental diseases (major depression, schizophrenia, neurocognitive disorders), while the cluster in yellow characterizes major causes of these illnesses (stigma, distress), as well as efforts and strategies to ameliorate these problems (social and family support, community adjustment). The blue cluster refers to current treatments and healthcare services to improve patients' quality of life.

As for the content analysis of abstracts by exploratory factor analysis, the top 50 emerging research domains are listed in [Table 3](#ijerph-16-01772-t003){ref-type="table"}. The most common domain came to unprotected sex behaviors, accounting for more than half of total cases. Depression in PLWH has also been explored through various aspects, including attributable causes (social stigma and discrimination, violence, substance abuse), affected issues and associated consequences (quality of life, medication adherence, suicidal ideation, and mortality), and possible interventions and coping strategies (medical care, and social support). Meanwhile, biomedical aspects, such as viral load and cell counts, and immune responses were not the choice of many researchers, as illustrated by the relatively low rank in the list (\#25 and \#35, respectively).

Exploratory factor analysis of abstracts' contents also materialized the co-occurrence of the most frequent topics ([Figure A1](#ijerph-16-01772-f0A1){ref-type="fig"}). Demographic and epidemiological characteristics of PLWH suffering from depressive symptoms and anxiety were grouped in the red cluster. Risk behaviors (sexual transmission, violence) and the interventions and preventions in different time courses (day, week(s), and year) were found to have strong correlation (blue nodes). Researchers also considered depressive responses in an immunological view (purple nodes), whereas such topics as neuropsychological performance, cognitive functioning, tests for symptoms and severity of depression, and specific patient groups did not show any apparent co-occurrence pattern with other terms or topics.

[Figure 4](#ijerph-16-01772-f004){ref-type="fig"} presents the most frequent terms co-occurring with intervention(s) or trial(s) in the content analysis of all abstracts. The scope of interventions related to depression among HIV/AIDS covered behavioral, sexual, and treatment adherence interventions, at either individual or community levels, involving interrelationships and social supports, and measurements of various outcomes, including physical (e.g., pain), psychological, and depressive symptoms. Meanwhile, randomized controlled trial(s), which were applied to measure medication adherence and quality of potential therapy, was apparently the most common type of study setting.

4. Discussion {#sec4-ijerph-16-01772}
=============

This study revealed the development of research on depression in PLWH in terms of quantity and current interests. Along with the significant increase of scientific literature volume, depression among HIV-infected patients has been extensively examined. Research landscapes related to this field include risk behaviors and attributable causes of depression in HIV population, effects of depression on health outcomes of PLWH, and interventions and health services for these particular subjects. Countries with large HIV populations, such as the United States of America, South Africa, Uganda, China, and India, possessed the highest number of empirical studies. Notable research gaps and future implications for further study on depression among PLWH are also discussed in this section.

In terms of collaborating framework, in addition to the regional collaboration, which is due to the similarities in socioeconomic characteristics, this research field has also witnessed the cooperation between the United States and other South East Asian nations, namely Thailand and Cambodia ([Figure 2](#ijerph-16-01772-f002){ref-type="fig"}). By 2018, the Thai-U.S. partnership on HIV vaccine development has lasted for 25 years and the U.S. government has invested millions of US dollars in Thai research programs for HIV evaluation and optimization, as well as provided Thailand with service delivery and technical support through the President's Emergency Plan for AIDS Relief (PEPFAR) since the fiscal year 2007 \[[@B22-ijerph-16-01772],[@B23-ijerph-16-01772]\]. Meanwhile, Cambodia has received more than \$150 million from USAID, which helped reduce the prevalence of adults with HIV and the HIV rate among sex workers to merely one third and provided roughly 80% of adult patients with adequate care and treatment \[[@B24-ijerph-16-01772]\]. With the help of the U.S., Thailand and Cambodia have earned international recognition as success stories in the fight against this global epidemic \[[@B24-ijerph-16-01772],[@B25-ijerph-16-01772]\].

Risky sex behaviors, including unprotected sexual activities and anal sex, have been the most researched topic in the top 50 research domains ([Table 3](#ijerph-16-01772-t003){ref-type="table"}). Nevertheless, there were limited studies set up in Thailand---the home to populations exhibiting those risk behaviors most frequently, such as sex workers, transgender people, and homosexual men or men who have sex with men (MSM), to name a few ([Table 2](#ijerph-16-01772-t002){ref-type="table"}). Since female sex workers are usually exposed to a high risk of sexually transmitted diseases, work-related violence, and unwanted pregnancy, and experience both perceived and self-stigma due to their work characteristics, the prevalence of major depression of this group has been reported to be higher compared to general population \[[@B26-ijerph-16-01772],[@B27-ijerph-16-01772],[@B28-ijerph-16-01772],[@B29-ijerph-16-01772]\]. Transgender people and MSM are also vulnerable to anxiety and depression, as they have to experience not only HIV-related discrimination and isolation but also prejudice against homosexuality \[[@B30-ijerph-16-01772],[@B31-ijerph-16-01772]\]. Despite the fact that same-sex marriage has been allowed in many countries, homosexuality is still a controversial topic in Asia, and there is currently no Asian nation officially legalizing same-sex marriage \[[@B16-ijerph-16-01772],[@B32-ijerph-16-01772]\]. Therefore, more study settings should be located in Asian developing countries, where the level of social judgement on the sex workers and LGBT community is relatively high, in order to demonstrate effective approaches to reach, test, and treat these key populations.

Most of the existing interventions are focused on reduction of risk behaviors and social stigma, rather than interventions that target the infected populations ([Figure 4](#ijerph-16-01772-f004){ref-type="fig"}). Since HIV is regarded as an incurable infection, it is essential to prevent incident HIV infections and the reduction of unprotected sex, injecting drugs, or substance abuse would lighten the global burden of HIV epidemic \[[@B33-ijerph-16-01772]\]. Additionally, stigma and discrimination, either perceived or self-stigma, is responsible for depressive symptoms in the majority of HIV-infected individuals \[[@B34-ijerph-16-01772]\]. Therefore, interventions addressing these problems would effectively lower the prevalence of HIV infection, in general, and depression among PLWH in particular.

Although the field of depression in PLWH has been extensively studied, biomedical aspects of this research topic deserve more attention, since such research topics as viral load or immune responses currently hold relatively low positions ([Table 3](#ijerph-16-01772-t003){ref-type="table"}). In addition to psychological and somatic symptoms, biological factors also contribute to depression among HIV patients. A number of studies have recognized that chronic viral infections, including HIV, are able to affect immune system and influence the way the central nervous system mediates psychological status, resulting in neuropsychiatric consequences \[[@B35-ijerph-16-01772],[@B36-ijerph-16-01772]\]. Biologically, HIV may trigger the release of inflammatory cytokines and induce sickness behaviors that are similar to depressive symptoms \[[@B37-ijerph-16-01772]\]. Additionally, while many antidepressants relieve the symptoms by elevating the level of a neurotransmitter called serotonin, HIV is capable of altering the precursor (tryptophan) and, thus, suppress the efficacy of the medications to a certain extent \[[@B38-ijerph-16-01772],[@B39-ijerph-16-01772]\]. Evidences of neuronal damages have been recorded only a year after HIV infections and it been has reported that the use of antiviral therapies and the stage of the disease are associated with worsening depression \[[@B40-ijerph-16-01772],[@B41-ijerph-16-01772],[@B42-ijerph-16-01772]\].

There are several implications arising from the current study. Taking Thailand and Cambodia as the role models, developing countries could seek for investments from the U.S., considering that the US government not only offers various funds and organizations targeting HIV populations but also succeeded in supporting other countries to deal with the issue of depression among PLWH. Additionally, more studies should be set up in countries where the most-at-risk subjects commonly reside, such as Asian developing countries, in order to understand their nature, as well as the demographic characteristics and contextual factors, thus establishing more practical interventions. On the other hand, the biological correlation between HIV infection and depression requires more intensive research, which may make a great contribution to the diagnostic procedure and treatments for depression among individuals suffering from HIV.

Even though we introduced a novel approach in summarizing and analyzing the extant literature, some limitations should be acknowledged. First, the involved databases were limited to only the Web of Sciences. Despite the fact that Web of Science contains the largest proportion of the literature of HIV/AIDS research, it is probably not fully representative of all data. Another limitation is that only publications in English were selected for this study. Additionally, the content analysis consisted solely of abstracts instead of full texts. Nevertheless, this modified bibliometric analysis puts forward a comprehensive overview of research trends as well as identifies current gaps in the literature of depression among PLWH.

5. Conclusions {#sec5-ijerph-16-01772}
==============

In conclusion, by using bibliometric and scientometric analysis, this study presented the global research trends and interests, pointed out the research gaps of available publications, and suggested several implications for depression of HIV-positive individuals. In spite of the fact that this field has attracted a great deal of attention and been extensively studied, more efforts should be made to fulfill the lack of empirical study in developing countries and biomedical investigation on the correlation between HIV and depression.

The following are available online at <https://www.mdpi.com/1660-4601/16/10/1772/s1>, Table S1: Search strategy on Web of Science.
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ijerph-16-01772-t001_Table 1

###### 

General characteristics of publications.

  Year Published   Total Number of Papers   Total Citations   Mean Cite Rate per Year   Total Usage Last 6 Month   Total Usage Last 5 Years   Mean Use Rate Last 6 Month   Mean Use Rate Last 5 Year
  ---------------- ------------------------ ----------------- ------------------------- -------------------------- -------------------------- ---------------------------- ---------------------------
  2017             428                      565               1.32                      663                        2018                       1.55                         0.94
  2016             378                      1775              2.35                      404                        3683                       1.07                         1.95
  2015             330                      2811              2.84                      272                        3896                       0.82                         2.36
  2014             329                      3978              3.02                      198                        4083                       0.60                         2.48
  2013             338                      5078              3.00                      187                        4867                       0.55                         2.88
  2012             323                      8434              4.35                      208                        4390                       0.64                         2.72
  2011             237                      6059              3.65                      123                        2680                       0.52                         2.26
  2010             248                      6525              3.29                      111                        2141                       0.45                         1.73
  2009             218                      6315              3.22                      102                        1758                       0.47                         1.61
  2008             193                      7629              3.95                      114                        1825                       0.59                         1.89
  2007             153                      7145              4.25                      107                        1516                       0.70                         1.98
  2006             181                      10,994            5.06                      130                        2044                       0.72                         2.26
  2005             147                      7174              3.75                      69                         1135                       0.47                         1.54
  2004             127                      5453              3.07                      53                         666                        0.42                         1.05
  2003             121                      6364              3.51                      64                         945                        0.53                         1.56
  2002             116                      5739              3.09                      46                         605                        0.40                         1.04
  2001             109                      8811              4.75                      49                         968                        0.45                         1.78
  2000             105                      7415              3.92                      63                         1026                       0.60                         1.95
  1999             85                       4077              2.52                      23                         343                        0.27                         0.81
  1998             109                      3682              1.69                      23                         405                        0.21                         0.74
  1997             108                      8473              3.74                      97                         1114                       0.90                         2.06
  1996             110                      4912              2.03                      24                         288                        0.22                         0.52
  1995             85                       2706              1.38                      13                         217                        0.15                         0.51
  1994             81                       2850              1.47                      9                          128                        0.11                         0.32
  1993             83                       3940              1.90                      13                         202                        0.16                         0.49
  1992             63                       3548              2.17                      12                         149                        0.19                         0.47
  1991             49                       2302              1.74                      5                          71                         0.10                         0.29
  1990             1                        24                0.86                      0                          1                          0.00                         0.20

Mean cite rate per year = total citations/\[total citations\*(2018-that year)\]. Total usage: total downloads. Mean use rate last 6 months = total usage last 6 months/total number of papers. Mean use rate last 5 years = total usage last 5 years/(total number of papers\*5).

ijerph-16-01772-t002_Table 2

###### 

Number of papers by countries as study settings.

  \#   Country Settings   Frequency   \%      \#   Country Settings     Frequency   \%
  ---- ------------------ ----------- ------- ---- -------------------- ----------- ------
  1    United States      432         22.7%   31   Haiti                13          0.7%
  2    South Africa       203         10.7%   32   Iran                 13          0.7%
  3    Uganda             102         5.4%    33   Hong Kong            10          0.5%
  4    China              89          4.7%    34   Spain                10          0.5%
  5    India              73          3.8%    35   Denmark              9           0.5%
  6    Ireland            73          3.8%    36   Jersey               9           0.5%
  7    Canada             62          3.3%    37   Dominica             8           0.4%
  8    Brazil             46          2.4%    38   Dominican Republic   8           0.4%
  9    Australia          43          2.3%    39   Georgia              8           0.4%
  10   United Kingdom     41          2.2%    40   Netherlands          8           0.4%
  11   Kenya              35          1.8%    41   Ukraine              8           0.4%
  12   Viet Nam           32          1.7%    42   Chile                7           0.4%
  13   Tanzania           28          1.5%    43   Germany              7           0.4%
  14   Niger              27          1.4%    44   Jamaica              7           0.4%
  15   Nigeria            27          1.4%    45   Lesotho              6           0.3%
  16   Puerto Rico        24          1.3%    46   Malaysia             6           0.3%
  17   Rwanda             24          1.3%    47   Peru                 6           0.3%
  18   Taiwan             22          1.2%    48   Sweden               6           0.3%
  19   Ethiopia           21          1.1%    49   Colombia             5           0.3%
  20   Mexico             21          1.1%    50   Ghana                5           0.3%
  21   Thailand           20          1.1%    51   Mali                 5           0.3%
  22   Zambia             18          0.9%    52   Namibia              5           0.3%
  23   Malawi             17          0.9%    53   Norway               5           0.3%
  24   Zimbabwe           17          0.9%    54   Russian Federation   5           0.3%
  25   Botswana           16          0.8%    55   Cambodia             4           0.2%
  26   France             16          0.8%    56   Congo                4           0.2%
  27   Japan              16          0.8%    57   Congo                4           0.2%
  28   Nepal              15          0.8%    58   Israel               4           0.2%
  29   Cameroon           14          0.7%    59   Senegal              4           0.2%
  30   Italy              14          0.7%    60   Singapore            4           0.2%

ijerph-16-01772-t003_Table 3

###### 

Top 50 research domains emerged from exploratory factor analysis of all abstracts' contents.

  No   Name                                     Keywords                                                                                                       Eigen Value   Freq   %cases
  ---- ---------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------- ------ --------
  1    Sex Sexual; Unprotected                  sex; unprotected; sexual; anal; partners; msm; risk; behaviors; prevention; behavior; men; partner; sexually   3.81          7005   54.74%
  2    Psychological Distress; Emotional        distress; psychological; emotional; anxiety; physical                                                          1.55          3364   45.28%
  3    Medical Care                             care; providers; medical; services; barriers; primary; interviews                                              1.81          3455   43.64%
  4    Depressed                                depressed; anxiety                                                                                             1.30          2035   40.62%
  5    Social Stigma                            stigma; discrimination; social; support; disclosure; perceived; experiences                                    2.39          3374   39.16%
  6    Psychiatric; Disorder                    psychiatric; disorder; disorders; major; interview; diagnosis                                                  2.89          3188   38.36%
  7    Coping Strategies; Social Support        coping; strategies; support; social                                                                            1.41          2705   35.55%
  8    Scale; Hospital                          scale; hospital; questionnaire; total; score                                                                   1.31          2390   33.07%
  9    Depressive                               depressive; symptoms                                                                                           1.29          2132   32.22%
  10   Antiretroviral                           antiretroviral; therapy; haart; adherence                                                                      2.66          2741   29.80%
  11   Adherence To Medication                  medication; adherence; medications; antiretroviral; taking                                                     1.33          2384   29.02%
  12   Cancer Pain; Chronic Diseases            cancer; pain; diseases; chronic; review; conditions                                                            1.64          1930   28.08%
  13   Mortality; Disease Progression           mortality; disease; progression; death                                                                         1.34          1680   26.89%
  14   Provide Evidence                         evidence; limited; review; trials; provide                                                                     1.39          1702   26.83%
  15   Neuropsychological; Memory Performance   neuropsychological; performance; neurocognitive; impairment; memory; cognitive; tests; function; functioning   2.76          2292   25.92%
  16   Violence (IPV); Partner                  ipv; violence; partner; women; pregnancy                                                                       1.93          1640   24.63%
  17   Disorder (PTSD)                          ptsd; stress; post; disorder                                                                                   1.70          1570   24.20%
  18   Randomized; Controlled Trial             randomized; trial; controlled; placebo; trials; intervention; efficacy                                         3.30          2193   24.20%
  19   Substance Abuse                          abuse; substance; alcohol; childhood                                                                           1.61          1800   23.60%
  20   Month Follow                             month; follow; period; year                                                                                    1.52          1579   23.19%
  21   Control                                  controls; control; subjects; seropositive                                                                      1.51          1422   22.95%
  22   Intervention Program                     program; community; intervention                                                                               1.46          1266   22.48%
  23   Examine                                  examine; purpose; relationships                                                                                1.30          1269   21.82%
  24   Drug Users                               users; drug; injection; cocaine                                                                                2.17          1457   20.79%
  25   Viral Load; Cells Count                  load; viral; count; counts; cells                                                                              1.92          1703   20.55%
  26   Test                                     testing; test; tested; tests                                                                                   1.42          1257   20.40%
  27   Gay Men                                  gay; bisexual; men                                                                                             1.88          1400   20.38%
  28   Life Quality                             quality; life; qol; hrqol                                                                                      2.09          1619   20.32%
  29   Human Immunodeficiency                   immunodeficiency; human; syndrome                                                                              2.26          1891   20.30%
  30   Side Effects                             effects; side                                                                                                  1.43          1142   19.77%
  31   Female                                   female; male; gender                                                                                           1.54          1168   19.03%
  32   Cross-Sectional                          sectional; cross; survey                                                                                       2.36          1703   18.80%
  33   Symptom Severity                         symptom; fatigue; sleep; severity; pain                                                                        1.59          1177   18.27%
  34   Children; Family Caregivers              children; caregivers; affected; mothers; family                                                                2.05          1241   18.00%
  35   Response                                 responses; response; immune                                                                                    1.25          976    16.07%
  36   Persons                                  persons; states                                                                                                1.28          756    14.57%
  37   Infections; Sexually                     infections; sexually; diseases                                                                                 1.27          883    14.43%
  38   Physical                                 physical                                                                                                       1.24          556    11.41%
  39   Perceived                                perceived; received                                                                                            1.26          600    11.10%
  40   Brain                                    brain; system                                                                                                  1.48          505    9.32%
  41   Case                                     cases; case                                                                                                    1.32          491    9.20%
  42   History                                  history                                                                                                        1.36          439    9.01%
  43   Youth; Adolescents                       youth; adolescents; young                                                                                      1.57          514    8.50%
  44   Adverse Events                           events; adverse                                                                                                1.39          488    8.48%
  45   South Africa                             africa; south                                                                                                  1.68          584    8.23%
  46   Work                                     workers; work                                                                                                  1.35          401    7.45%
  47   Long-Term                                long; term                                                                                                     2.15          510    6.69%
  48   Suicidal Ideation                        suicidal; ideation; suicide                                                                                    1.98          447    5.58%
  49   Hepatitis C Virus (HCV)                  hcv; hepatitis                                                                                                 1.79          360    5.25%
  50   Testosterone                             testosterone; body                                                                                             1.37          238    4.52%
